What does Guardant Health do?
Guardant Health, is company which is committed to positively and significantly impacting patient health through tech breakthroughs in oncology which addresses long standing unmet needs. The company is led by a seasoned management team which comprises of successful serial entrepreneurs and leaders in rare cell diagnostics and next gen sequencing and is closely advised by medical steering committee led by an oncologist from the leading cancer centres across North America and abroad.
How much Guardant Health was funded?
Guardant Health raised $100M in Series D on January 7, 2016 from Felicis Ventures, Formation 8, Heritage Group, Lightspeed Venture Partners, Pejman Mar Ventures, Khosla Ventures,Sequoia Capital and OrbiMed Advisors
Previous funding
- $10M in Series A on February 11, 2014 from Sequoia Capital and Farzad (Zod) Nazem
- $30M in Series B on April 22, 2014 from Sequoia Capital, Pejman Mar Ventures, Khosla Ventures, Signatures Capital andBobby Yazdani.
- Undisclosed amount on June 8, 2012 on Plug & Play Ventures
- $50M in Series C on February 3, 2015 from Sequoia Capital, Formation 8, Lightspeed Venture Partners andKhosla Ventures
What is next for Guardant Health?
Guardant Health plans to use the latest funding raised for expanding the technical and commercial lead of Guardant 360, which is the world’s 1st comprehensive, non-invasive genomic sequencing test for cancer. This test helps the physicians in identifying genomic alterations in patients with advance cancers, without the risk, cost or pain caused by invasive biopsies. The company also plans to use the funds for further expanding its digital sequencing platform into new product line which shall address the total cancer care continuum.
More about Guardant Health
Guardant Health was founded by Helmy Eltoukhy and AmirAli Talasaz. It has its headquarters in Redwood City, CA. The company mission is developing breakthrough diagnostic technologies which can transform cancer from a disease which kills silently to a more manageable one.